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Retrovirus pseudotypes are a highly tractable model used to study the entry pathways of
enveloped viruses. This model has been extensively applied to the study of the hepatitis C virus
(HCV) entry pathway, preclinical screening of antiviral antibodies and for assessing the
phenotype of patient-derived viruses using HCV pseudoparticles (HCVpp) possessing the HCV
E1 and E2 glycoproteins. However, not all patient-isolated clones produce particles that are
infectious in this model. This study investigated factors that might limit phenotyping of patient-
isolated HCV glycoproteins. Genetically related HCV glycoproteins from quasispecies in
individual patients were discovered to behave very differently in this entry model. Empirical
optimization of the ratio of packaging construct and glycoprotein-encoding plasmid was required
for successful HCVpp genesis for different clones. The selection of retroviral packaging
construct also influenced the function of HCV pseudoparticles. Some glycoprotein constructs
tolerated a wide range of assay parameters, while others were much more sensitive to
alterations. Furthermore, glycoproteins previously characterized as unable to mediate entry were
found to be functional. These findings were validated using chimeric cell-cultured HCV bearing
these glycoproteins. Using the same empirical approach we demonstrated that generation of
infectious ebolavirus pseudoviruses (EBOVpv) was also sensitive to the amount and ratio of
plasmids used, and that protocols for optimal production of these pseudoviruses are dependent
on the exact virus glycoprotein construct. These findings demonstrate that it is crucial for studies
utilizing pseudoviruses to conduct empirical optimization of pseudotype production for each
specific glycoprotein sequence to achieve optimal titres and facilitate accurate phenotyping.
INTRODUCTION
Chronic hepatitis C virus (HCV) infection affects approxi-
mately 3% of the world’s population. Infection can result in
fibrosis, decompensated liver disease and hepatocellular carci-
noma. Genetic variability is a key feature of HCV, with viral iso-
lates classified into six major genotypes that differ by up to
30% at the nucleotide level. The genomes of isolates within a
genotype can differ by up to 15%. Furthermore the virus exists
as a quasispecies population in an infected host, with approxi-
mately 1% of the genome varying between strains (Nasu et al.,
2011). This extreme variability contributes to the persistent
nature of HCV infection and presents a significant barrier to
developing broadly active therapies and vaccines.
HCV possesses a complex entry pathway mediated by the HCV
E1 and E2 glycoproteins, which bind to receptors and facilitate
membrane fusion [reviewed in Tarr et al. (2015)]. These glyco-
proteins display the greatest level of genetic diversity in the
HCV genome (Nasu et al., 2011), yet receptor interactions are
highly conserved between genetically distinct strains (Gottwein
et al., 2009; Lavillette et al., 2005). This conserved entry
pathway highlights the potential for vaccine-induced
broadly neutralizing antibodies. Development of an effective
vaccine remains a key challenge for the eradication of HCV
infection and assessing the potency of neutralizing antibodies
against strains representing in vivo infections is critical to this
goal. In vitro assessment of the breadth of HCV neutralization
has predominantly utilized two assays. First, the cell-culture
E1/E2 nucleotide sequences described in this study have been depos-
ited in GenBank under the accession number (KU213640).
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replicating molecular clone JFH-1 and chimeras derived from
this virus possessing the structural genes of other viruses pro-
vide a method of assessing neutralization of small panels of
genetically diverse viruses (Carlsen et al., 2014; Pedersen et al.,
2013). Second, retroviral pseudotypes (HCV pseudoparticles;
HCVpp), which can be rapidly reconstituted with the HCV E1
and E2 glycoproteins of diverse strains, permit assessment of
neutralization against a wide range of virus isolates (Bailey
et al., 2015; Fafi-Kremer et al., 2010; Osburn et al., 2014;
Urbanowicz et al., 2015). This assay was instrumental in identi-
fying common HCV entry pathways utilizing conserved host
cellular receptors that interact with the HCV glycoproteins
(Bartosch et al., 2003c; Evans et al., 2007; Lavillette et al., 2005).
Retroviral pseudoparticles have been utilized to investigate
the nature of infectious isolates representing the quasispecies
variants in natural HCV infections (Fafi-Kremer et al., 2010;
Osburn et al., 2014). However, variable success recovering
functioning glycoprotein sequences from HCV-infected
individuals between studies indicated that in vitro artefacts
might contribute to the failure to identify infectious clones
in some patients. This could lead to bias in the phenotype of
HCV strains that are selected for analysis of entry inhibitors
and therefore provide an unrepresentative view of the prop-
erties of glycoproteins representing circulating HCV strains.
While the methods for producing HCVpp are generally stan-
dardized (Bartosch et al., 2003a; Hsu et al., 2003; Tarr et al.,
2007), successful generation of infectious pseudotypes is
dependent on many factors [reviewed in King et al. (2016)].
We previously reported that about 24–27% of glycoprotein
clones isolated from chronic and acute infections yield infec-
tious HCVpp (Lavillette et al., 2005; Urbanowicz et al.,
2015). It was observed that even closely related sequences
contrasted in their ability to produce infectious particles. To
investigate this further, the properties of HCV pseudopar-
ticles bearing patient-derived HCV glycoproteins were
investigated. It was discovered that the infectivity of patient-
derived E1/E2 glycoproteins previously determined to be
non-functional is influenced by expression protocols used to
generate HCVpp. Furthermore, infectivity was dependent
on the species of the packaging construct used. To determine
if these potential artefacts occur in pseudotypes representing
other variable RNA viruses, we also compared infectivity of
pseudoviruses incorporating genetically related ebolavirus
glycoproteins (EBOVpv). Varying the EBOVpv genesis pro-
tocol had similar effects on EBOVpv on infectivity. This
work has implications for future studies of not only HCV
patient strains, but also for the investigation of other viruses
that rely on pseudotyped entry models.
RESULTS
Infectivity phenotype of HCV E1/E2
pseudoparticles is dependent on a fine balance of
plasmid expression
HCV pseudoparticles were generated using a standard
three-plasmid system, utilizing murine leukaemia virus
backbone/luciferase reporter plasmids (Bartosch et al.,
2003a) and HCV E1/E2 proteins expressed in cis in a
pcDNA3.1 plasmid (Tarr et al., 2007) (Fig. 1). A panel of
493 E1/E2 clones from 63 different HCV-infected patients
were screened for infectivity, as previously described
(Urbanowicz et al., 2015). Of these, only 118 clones (24%)
were identified as being infectious in our entry assay
(Fig. 2). Infectious clones were not absolutely segregated by
genotype or subtype, suggesting that lack of infectivity is
dependent on isolate-specific mutations in these genes.
However, in some cases all E1/E2 clones recovered from
individual patients were non-infectious. The proportion of
infectious clones from patients harbouring genotype 3
(5%) and genotype 5 (8%) virus populations were lower
than other genotypes. Repeated assays with these clones
determined the batch-to-batch variation in luciferase signal
to be <20% for an individual glycoprotein clone.
Having observed this discrepancy in infectivity between
genetically similar clones we investigated whether the
amount of HCV glycoprotein construct delivered to the
transfected cells influenced infectivity of the particles pro-
duced. A series of transfections was performed with a
matrix of serial dilutions of the plasmid preparations of
both the H77c (AF011751) reference consensus sequence
and the patient-derived clone UKN2A1.2 (Fig. 3). Using
supernatants from cells transfected with a fixed amount of
the luciferase reporter gene and varying amounts of the
MLV packaging construct and the HCV E1/E2 glycoprotein
construct, infectivity values were determined for H77c
(Fig. 3a) and UKN2A1.2 (Fig. 3b). The ratio of plasmids
encoding the packaging construct and the glycoprotein con-
struct was critical to the observed infectivity – at the
extremes of concentrations analysed, little luciferase signal
was observed for either clone. Maximum infectivity for H77
HCVpp occurred when either 2 ug or 0.5 ug of each plas-
mid was delivered to HEK293T cells. While infectivity of
H77c HCVpp tolerated a broad range of concentrations of
E1/E2 and packaging plasmids, the combinations of plas-
mid concentrations that resulted in maximal HCVpp infec-
tivity for UKN2A1.2 were more restricted (Fig. 3b). As it
was plausible that the differences in plasmid quantities used
for transfection affected the incorporation of glycoproteins
into pseudoparticles, neutralization assays were performed
on preparations of virus expressed with different amounts
of plasmid (Fig. 3c, d). However, no significant differences
in neutralization curves were observed.
Differences in infectivity between closely related
viruses using the HCVpp model
To determine if this experimental artefact contributed to
the lack of infectivity observed for some patient isolates in
our original panel, closely related sequences with different
infectivity phenotypes in the HCVpp assay were analysed.
Sixteen E1/E2 ORF clones from a well characterized treat-
ment-naïve patient were selected [patient UKN1A14
(Brown et al., 2005; Curran et al., 2002) (Fig. 4a)]. HCVpp
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assays revealed contrasting patterns of infectivity with the
glycoproteins using standard techniques (Fig. 4b).
Nucleotide diversity across all the E1/E2 clones was <4%.
Clones that resulted in infectious particles could differ by
phCMV5349
-gag/pol
pTG126
-luc
pcDNA3.1
-E1/E2
5′ LTR 3′ LTR
MLV gag
Gag
Luc
E1
E1/E2
E2pol∆envPCMV
PCMV
PCMV
Fig. 1. Experimental setup for HCV pseudotype production in this study. Transfections were prepared with a fixed amount of
the reporter plasmid pTG126, encoding an RNA transcript with a packaging signal ( ) and a luciferase reporter gene under
the control of a CMV IE promoter, with flanking MLV long terminal repeats (LTRs). This plasmid was co-transfected with varying
quantities of both the E1/E2-encoding plasmid (derived from pcDNA3.1) and the MLV Gag/Pol-encoding packaging plasmid
(phCMV5349) to create a matrix of transfections for each patient-derived clone. HEK293T cells were transfected with the mix-
ture of plasmids, and the pseudotypes generated were used to infect HuH7 cells in a 96-well format. Infectivity was deter-
mined as RLU from the expressed reporter gene in the HuH7 cells.
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as little as a single amino acid from those that did not. To
determine if plasmid concentrations affected infectivity,
two clones were selected: one that gave relative lumines-
cence signal below the threshold of infectivity
(UKN1A14.40), and one clone that gave a similar signal to
the reference H77c (UKN1A14.38). These two clones dif-
fered by a single amino acid at position (H691R) in the
E1/E2 coding region (Fig. 4c). Pseudoparticles possessing
these glycoproteins were produced with varying amounts
of E1/E2 plasmid and packaging vector. Despite the com-
mon plasmid backbone and promoter sequences in these
clones, UKN1A14.40 (Fig. 5a) had contrasting patterns of
infection to UKN1A14.38 (Fig. 5c). For UKN1A14.38, the
greatest signal was achieved when using greater amounts
(1.6 µg) of both packaging plasmid and glycoprotein-
encoding plasmid, similar to those used for H77c. In con-
trast, the highest signal for UKN1A14.40 was achieved
with 25-fold less E1/E2-encoding plasmid (0.064 µg) and
1.6 µg of packaging vector. Consistent with our earlier
observation, UKN1A14.40 was not infectious when using
standard assay parameters. To determine if infectivity was
associated with better incorporation of MLV capsid or
HCV glycoproteins into HCVpp, Western blots of sucrose
cushion-purified pseudoparticles were performed and
compared with the protein expression in producer 293T
cell lysates (Fig. 5b, d). As expected, E2 was only observed
in HCVpp preparations that contained detectable capsid
protein. However, E2 was not detected in all preparations
where capsid was detected, and detection of E2 did not
correlate with the production of infectious pseudoparticles.
For UKN1A14.40, E2 was only detectable when the great-
est amount of MLV packaging plasmid was used, despite
this coinciding with only 50–60% maximal signal for this
isolate. Similarly, infectivity was not always associated with
detectable MLV-capsid protein in the pelleted pseudo-
particles. It was observed that increasing the amount of
the E1/E2-encoding plasmid resulted in reduced expres-
sion of capsid protein in producer cells. Glycoprotein
expression in the UKN1A14.38-transfected cells was more
readily detected. Comparison of the sequences of these
clones revealed all glycoproteins possessed identical epito-
pes for mAbs AP33/ALP98 (aa412-420 and aa644-641,
respectively) used for detection in Western blot (Fig. 4c).
As such, detectable expression of UKN1A14.38 E1/E2
occurred over a larger range of plasmid concentrations,
although the expression did not correlate directly with
production of infectious HCVpp. The expression of E2 in
Western blots of lysates of cells transfected with
UKN1A14.40 or UKN1A14.38 was detected as two discrete
bands, with an additional, lower molecular weight protein
being visible when expression of E2 was high. The smaller
bands were more evident for UKN1A14.40 (Fig. 5b), but
was also present at a low level in blots of UKN1A14.38
(Fig. 5d). Detection of this band did not correlate with
infectivity of particles produced from these transfections.
Selection of pseudotype packaging vector
influences infectivity of HCVpp
Having established that the amounts of glycoprotein-
encoding and MLV packaging plasmids delivered to pro-
ducer cells influenced the ability to recover infectious
HCVpp, the influence of the species of retrovirus used as
packaging construct was investigated (Fig. 6). Using a small
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Fig. 2. Frequency of recovery of functional HCV glycoproteins using an MLV-based retroviral pseudoparticle assay. Patient
isolates were screened using standard assay parameters as previously described (Tarr et al., 2007). (a) From a total of 63
patients, 118 E1/E2 clones were defined as functional in this assay (Urbanowicz et al., 2015). The majority of E1/E2 clones
(76%) were non-functional in this assay. The total number of clones screened for each genotype is noted above each bar. The
proportion of functional clones (green) and the proportion of non-functional clones (blue) is displayed. When segregated by
genotype, the proportion of functional genotype 3 and genotype 5 clones was lower than genotypes 1, 2 or 6. (b) Frequency
of recovery of functional HCV glycoproteins from HCV-infected individuals. The total number of individuals infected with each
genotype is highlighted above each bar. Again, the proportion of patients with functional clones (green) was lower for genotype
3 and genotype 5.
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panel of pcDNA3.1-cloned E1/E2 sequences that have pre-
viously been determined as infectious in an MLV-based
pseudotype assay (Lavillette et al., 2005; Owsianka et al.,
2005), pseudoparticles were generated using either MLV
packaging plasmids or HIV-1-based (pNL4.3) packaging
plasmids. Again, large differences in infectivity were
observed (Fig. 6a). Some E1/E2 sequences were equally
infectious in both model systems, including H77,
UKN1A20.8, UKN2A1.2 and UKN5.15.7. However, greater
than 100-fold higher infectivity was observed for some
clones with MLV backbones system compared to HIV-1
backbones, including UKN1B12.16, UKN3A13.6 and
UKN6.5.8. While none of the HCV E1/E2 clones gave
higher signal in an HIV-based backbone, infectivity of the
VSV-G control pseudovirus was a >1000-fold higher signal
in the HIV-1-based pseudoviruses compared to MLV-based
pseudoviruses. Comparison of the infectivity of the two
selected UKN1A14 clones, using the two packaging con-
structs, showed that the phenotype of each was comparable
in the two systems (Fig. 6b). Using standard assay parame-
ters, UKN1A14.40 did not generate a signal significantly
above the assay threshold with either packaging system,
while the signal achieved with UKN1A14.38 was compara-
ble for both packaging vectors.
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Fig. 3. Plasmid quantity affects the infectivity of pseudoparticles generated with standard reference HCV envelope glyco-
proteins. (a and b) Transfection matrices were prepared for H77 (Owsianka et al., 2006) and clone UKN2A1.2 (Lavillette et al.,
2005) with the resulting pseudoparticle preparations used to infect HuH7 cells. Graphs are presented as x-y contour plots of
plasmid concentrations, with increasing normalized luciferase signal indicated by darkening blue colour. Signals were normal-
ized against the maximal signal achieved for either H77 (~10000 RLU), UKN2A1.2 (~5000 RLU) or that achieved with the
negative control preparation (DE1/E2; ~100 RLU). Shades of blue represent the normalized infectivity data stratified into 20%
increments. HCVpp preparations with high signal were selected for neutralization assays (red, yellow and green points). (c and
d) Neutralization of HCVpp prepared with different plasmid concentrations. Preparations were incubated with defined concen-
trations of the HCV-neutralizing mouse monoclonal antibody AP33. No differences were observed in the neutralization sensitiv-
ity of the particles.
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Fig. 4. HCVpp infection mediated by E1/E2 genes of closely related members of an HCV quasispecies. (a) The E1/E2 coding
region was amplified by RT-PCR from a genotype 1a-infected patient (equivalent to amino acids 171–746 of the reference
H77c clone). Maximum likelihood phylogenetic analysis was performed using a WAG model as implemented in MEGA 6.0.
Bootstrap analysis of phylogeny using 1000 replicates was performed and values >80 are highlighted. (b) MLV-based HCVpp
each possessing an E1/E2 clone were screened for infectivity in HuH7 cells, using standard plasmid concentrations for
HCVpp genesis. Seven of the 16 isolated clones (. ) were defined as functional (greater than 3 background signal generated
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Patient-derived E1/E2 glycoproteins are
infectious in an HCVcc model of infection
To confirm if the E1/E2 glycoproteins facilitated infection
in the context of a full-length replicating virus, HCVcc chi-
meras derived from an H77/JFH-1 clone (Reyes-del Valle
et al., 2012) were generated with the E1/E2 genes of either
UKN1A14.40 or UKN1A14.38. The break points for these
chimeras were at amino acid residues 171 and 734 (refer-
enced to the H77c genome), including the polymorphisms
at aa179 and aa691. Each of these clones formed infectious
viruses with titres approximately 10-fold higher than the
H77c control (Fig. 7). Viruses sampled 24 or 96 h after elec-
troporation of naïve HuH7 cells had equivalent infectious
titres, irrespective of the patterns of infectivity observed in
the HCVpp system.
Infectivity of pseudoviruses bearing ebolavirus
glycoproteins is sensitive to changes in plasmid
quantities and selection of packaging vector
To investigate whether the patterns of infectivity observed
for HCVpp generated with different amounts of plasmids
also affected other virus pseudotypes, we performed the
same matrix of transfections using plasmids encoding the
GP1,2 of three ebolaviruses: Zaire ebolavirus H.sapiens-tc/
COD/1976/Yambuku-Mayinga (Mayinga EBOV), Zaire
ebolavirus H.sapiens-wt/GIN/2014/Makona-Gueckedou-
C07 (Makona EBOV) and Reston virus M.fascicularis-tc/
USA/1989/Philippines89-Pennsylvania (RESTV). Again we
observed that the amount of glycoprotein construct and
packaging vector plasmids used to create pseudoviruses
greatly affected the ability to recover infectious particles
(Fig. 8a–c). In contrast to HCVpp, the greatest infectivity of
Mayinga EBOVpv occurred with much lower concentra-
tions of the MLV packaging plasmid (0.32 µg) and the gly-
coprotein-encoding plasmid (0.032 µg). Makona EBOVpv
required even less glycoprotein (0.0064 µg), whereas RESTV
infectivity was greatest when using 0.32 µg packaging vector
and 0.8 µg GP1,2 plasmid. We also investigated the influence
of the species of retrovirus used as packaging construct
(Fig. 8d). As with the HCVpp, the differences observed
were strain specific, although the HIV-1 packaging con-
struct consistently provided higher levels of infectivity.
RESTVpv had a sixfold increase in infectivity with the HIV-
1 backbone. Both Zaire EBOVpv strains had a twofold
increase of signal with the HIV-1 backbone compared to
the MLV-based pseudoviruses. These differences highlight
the need to optimize transfection protocols for each indi-
vidual virus before assessing relative infectivity and per-
forming inhibition assays.
DISCUSSION
Retroviral pseudotypes are a flexible platform for assessing
the function of glycoproteins isolated from a wide range of
enveloped virus species, including hepaciviruses (Bartosch
et al., 2003a), filoviruses (Wool-Lewis & Bates, 1998), retro-
viruses (Li et al., 2005), lyssaviruses (Wright et al., 2009),
influenza viruses (Temperton et al., 2007) and arenaviruses
(Vela et al., 2007). However, there have been challenges to
reliable recovery of infectious viruses from polymorphic
HCV populations. Some studies identified high proportions
of infectious patient-isolated E1/E2 clones (Dowd et al.,
2009; Fafi-Kremer et al., 2010), while others recovered
lower frequencies of virus clones that are infectious in
HCVpp assay (Lavillette et al., 2005; McKeating et al., 2004;
Urbanowicz et al., 2015). As such, the use of the pseudopar-
ticles platform might create a bias towards the selection of
particular strains, which do not necessarily represent the
broader range of circulating virus isolates. The data pre-
sented here offers a potential explanation for the discrepan-
cies in the recovery frequency of infectious patient-isolated
clones between studies, and develops approaches to expand
the pool of functional HCVpp clones. Differences in the
amounts of plasmid used when screening new patient-
isolated glycoproteins might influence the functionality of
the particles produced, as shown for reference clones that
have previously been demonstrated to be infectious. We
examined closely related E1/E2 sequences recovered from a
single patient. The infectivity of the phenotype of E1/E2
clones using standard HCVpp assay parameters could be
switched by a single non-synonymous nucleotide substitu-
tion in the E2 protein, highlighting the sensitivity of the sys-
tem to small, biologically relevant genetic changes in
populations. This is consistent with previous reports of the
sensitivity of HCVpp to in vitro mutation (Owsianka et al.,
2006). Previous studies have described naturally occurring
variants that were not tolerated in HCVpp entry assays
(Keck et al., 2009) and E1/E2 mutations that were tolerated
differently in the HCVpp and HCVcc models (Goffard
et al., 2005; Helle et al., 2010; Russell et al., 2009).
In addition to the impact of the quantity of packaging con-
struct used for HCVpp, we also observed that the species of
packaging construct influences infectivity. Previous studies
screening HCV glycoprotein function have generally been
performed using only one of two retrovirus pseudotype
platforms, utilizing either HIV-1 (Hsu et al., 2003) or MLV-
based backbones (Bartosch et al., 2003b). Although these
approaches are generally comparable in preparation, read-
out and interpretation, there is very little evidence of direct
comparisons of these two systems with different HCV
with pseudotypes in the absence of glycoprotein, labelled as DE1/E2), although relative infectivity values varied widely. (c)
Alignment of the E1/E2 coding regions of patient-derived clones UKN1A14.38, UKN1A14.40, UKN1A14.42, UKN1A14.43
and UKN1A14.44. The hypervariable region 1 (HVR1) is highlighted in yellow, the HVR2 is highlighted in red. Amino acid poly-
morphisms are highlighted between the closely related strains. The protease cleavage sites between Core, E1 signal peptide,
E1 and E2 regions are highlighted with arrows.
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Fig. 5. HCVpp infectivity and protein incorporation into pseudoparticles. (a) Infectivity of patient clone UKN1A14.40. Pseu-
doparticles were made with a matrix of varying quantities of the plasmids encoding packaging vector and E1/E2 glycopro-
teins. Relative infectivity was normalized to the greatest signal observed (~10000 RLU) and the signal achieved with a
negative control preparation (DE1/E2). The graph is presented as an x-y contour plot of Gag- and E1/E2-encoding plasmid
concentrations. Greater infectivity is presented as darker blue, stratified into 20% increments, normalized to maximal infectiv-
ity. (b) Western blotting of transfected cell lysates of cells producing UKN1A14.40 HCVpp, using anti-E2 mAbs AP33 and
ALP98 (upper panel), and pelleted pseudoparticles with AP33/ALP98 (middle panel) or anti-MLV CA (lower panel). The rela-
tive infectivity for each combination of plasmids is displayed as the shade of blue corresponding to the scale presented in
panel (a). Very little incorporation of E2 was observed, while capsids were detected when using greater concentrations of
the packaging vector. (c) HCVpp infectivity pseudoparticles representing patient clone UKN1A14.38. Pseudoparticles were
made with a matrix of varying quantities of the plasmids encoding packaging vector and E1/E2 glycoproteins. Relative infec-
tivity was normalized to the greatest signal observed (~10000 RLU). Shades of blue represent the normalized infectivity data
in 20% increments. (d) Western blotting of transfected cell lysates producing UKN1A14.38 HCVpp, using anti-E2 antibodies
AP33 and ALP98 (upper panel), and pelleted pseudoparticles with AP33/ALP98 (middle panel) or anti-MLV CA (lower
panel). The relative infectivity for each combination of plasmids is displayed as the shade of blue corresponding to the scale
presented in panel (c). Incorporation of E2 was observed when either 8 or 1.6 µg of packaging vector was used, while cap-
sids were detected at all concentrations of the packaging vector. Greater concentrations of glycoprotein plasmid resulted in
reduced expression of capsid.
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glycoproteins, although assembly has been compared in
MLV and SIV-based vectors (Sandrin & Cosset, 2006).
HCV glycoprotein-encoding constructs that were initially
screened in the MLV-based HCVpp assay have been found
to be non-infectious in the HIV-1-based HCVpp assay,
leading to selection of specific clones for neutralization
experiments based on their ability to give reproducible
infectivity (Giang et al., 2012). Methods such as ‘spinocula-
tion’, concentration of virus preparations with sucrose
cushion centrifugation or addition of polybrene have been
used to improve infection of these particles (Giang et al.,
2012; Keck et al., 2012; McKeating et al., 2004). Here we
demonstrated that selection of an appropriate retrovirus
backbone is potentially critical to the infectivity phenotype
of a patient-isolated glycoprotein construct in HCVpp. This
demonstrates that infectivity phenotype cannot necessarily
be compared between MLV- and HIV-based systems, and
that care should be taken when investigating the effects of
mutations in the two systems. However, the finding that the
patient-derived clones tested here facilitated infection in the
context of a chimeric HCVcc virus suggests that HCVpp
systems can underestimate the infectious potential of some
patient-isolated virus glycoprotein variants.
One previously described determinant of strain-dependent
HCVpp infection is the presence of an intact Core protein
(aa1-191) at the N-terminus of the glycoprotein construct.
This has been proposed to be essential for efficient forma-
tion of pseudoparticles in a strain-dependent manner
(Shukla et al., 2010), with JFH-1pp requiring intact Core,
but H77 requiring only the C-terminal 21 amino acids.
However, it was found that infectious pseudoparticles were
generated for a large number of clones, including JFH-1,
when only the last 21 amino acids of Core/E1 signal peptide
were included (Urbanowicz et al., 2015).
The direct cause of the differences in production of infec-
tious particles, when varying concentrations of plasmids
were used to generate pseudotypes, requires further inves-
tigation. Reliable glycoprotein incorporation does not
appear to be an effective predictor of HCVpp entry, as
very low levels of the HCV glycoproteins (undetectable by
Western blot) were able to mediate infection in our assays.
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This is consistent with previous analysis of sucrose-gradi-
ent sedimented HCVpp preparations, where fractions con-
taining infectious pseudoparticles were associated with
detectable HIV-1 p24, but not HCV E2 (Flint et al., 2004).
More sensitive assays will be required to assess the amount
of glycoprotein required to mediate successful pseudotype
entry. There may be many reasons for the reduction in
production of infectious particles with increased glycopro-
tein expression. Expression could result in greater autoph-
agy of expressed proteins, or reduced retrovirus budding.
It is possible that increased expression of viral glycopro-
teins results in increased toxicity to the producer cells,
affecting release of infectious particles. Indeed, the ebolavi-
rus glycoproteins have been demonstrated to have toxic
effects on producer cells (Sullivan et al., 2005; Yang et al.,
2000). Greater analysis of the effects of glycoprotein
expression on HEK293T cells is warranted. Mohan and
colleagues have recently shown that reducing the amount
of EBOV GP1,2 plasmid increases observed infectivity
(Mohan et al., 2015). Our study of HCV glycoprotein
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incorporation is consistent with these data and, varying
the amount of the packaging vector, introduces a new fac-
tor that influences infectivity in addition to the distribu-
tion or toxicity of the glycoprotein. It is also plausible that
balancing the delivery of plasmids encoding the packaging
vector and glycoproteins means that there is competition
for expression of the two constructs from the common
promoter. This could be further investigated by using dif-
ferent promoters for the different elements of the pseudo-
type, or introducing an additional irrelevant gene under
the action of a CMV promoter.
The differences in infectivity of pseudoparticles generated with
HIV-1 or MLV backbones was also intriguing, suggesting that
incorporation of different isolates of the HCV glycoproteins
into retroviral particles is dependent on the specific assembly
of the packaging virus. Subtle differences in the assembly of
the two retroviruses may influence incorporation of the glyco-
proteins into infectious particles in an E1/E2-specific manner.
For example, differences in assembly site influence incorpo-
ration of the feline endogenous retrovirus RD114 glycoprotein
(Sandrin et al., 2004), and the Ebola GP1, 2 (Leung et al., 2008).
HCV glycoproteins are likely to be incorporated into MLV-
based pseudoparticles in an intracellular compartment.
Genetic variation in the E1/E2 glycoproteins could alter their
cellular localization, resulting in different interactions with cel-
lular chaperones and subsequent incorporation into particles.
Chaperone interactions are dependent on the presence of viral
glycans (Choukhi et al., 1998), and while the genetic variation
observed in our virus population did not appear to affect the
presence of N-linked glycosylation sequons, we did observe
two discrete bands representing the E2 glycoprotein in our
Western blots. It is plausible that these are differentially glyco-
sylated forms of the protein, as described previously (Chapel
et al., 2007; Goffard et al., 2005). High-resolution fluorescence
microscopy would be required to resolve the fine differences in
intracellular localization of these HCV glycoproteins. It will be
important to perform these experiments in the context of our
chimeric HCV viruses. The glycoprotein construct can influ-
ence the site of Gag/glycoprotein co-localization (Bouard et al.,
2007; Sandrin & Cosset, 2006), and interact with HIV-1 Vpu
resulting in depleted levels of intracellular Env (Christodoulo-
poulos et al., 2010). As a consequence, incompatibilities
between some glycoprotein/packaging constructs have been
observed (Christodoulopoulos & Cannon, 2001). It remains to
be determined if individual viral polymorphisms affect the
localization with Gag, influencing incorporation into pseudo-
particles or authentic virus particles.
In summary, the demonstration that artefacts of HCVpp
assays can result in underestimation of the functional
capacity of patient-isolated E1/E2 glycoproteins to mediate
entry into permissive cells highlights the need for better
models to investigate the consequences of genetic poly-
morphisms on HCV entry and neutralization using panels
of well-validated glycoprotein clones. We have recently
described the generation of a panel of HCV E1/E2 clones
that were functional in HCVpp, representing 24% of the
HCV sequences tested (Urbanowicz et al., 2015). While
testing different combinations of plasmid concentrations is
technically laborious, future screening of new isolates and
mutant E1/E2 clones for the ability to mediate entry in an
HCVpp model should take this experimental artefact into
account. While we have not extensively tested all of the
clones we initially screened to be negative in HCVpp assay,
we are now performing comparisons of HCVpp and
HCVcc chimeras to determine the infectious phenotype of
a much broader panel of isolates. It is likely that HCVpp
when generated using optimized protocols will yield E1/E2
that is functionality more predictive of the phenotype in
cell-cultured HCV. Care must also be taken when prepar-
ing pseudotypes bearing the glycoproteins of other viruses.
This is particularly important in establishing entry assays
for newly emerging highly pathogenic viruses that rely on
pseudotypes as a model for entry.
METHODS
The E1/E2 genes were cloned from RNA extracted from the serum of
chronically infected patients using previously described methods (Tarr
et al., 2007). PCR-amplified E1/E2 clones were ligated into the
pcDNA3.1D-V5-His-TOPO vector (Life Technologies) and clones
selected. Transfection-quality plasmids were prepared from transformed
cultures of TOP10 cells (Life Technologies) using endotoxin-free
GeneluteTM HP Midiprep kits (Sigma). DNA quality was assessed by
agarose gel electrophoresis and quantified by spectrophotometry at 260/
280 nm using a Nanodrop (Thermo). All plasmids possessed A260/
A280 ratios of ~1.8.
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Retroviral pseudotypes with patient-derived HCV E1/E2 clones were
initially prepared using HEK293T cells as described previously (Tarr
et al., 2007), based on the protocols described by Bartosch and col-
leagues (Bartosch et al., 2003a, b). A luciferase-encoding reporter plas-
mid (pTG126) and an MLV Gag/Pol-encoding packaging construct
(phCMV-5349) were kind gifts from François-Loïc Cosset. Briefly,
1.2106 HEK293T cells were seeded overnight in a 10 cm diameter
Primaria-coated dish (Corning) in 10 ml of Dulbecco’s Modified Eagle
Medium (DMEM, Gibco) supplemented with non-essential amino
acids and heat-inactivated FBS (both Gibco). Transfections were per-
formed with 2 µg of each of three plasmids (Fig. 1) using 24 µl cationic
polymer transfection reagent (Polyethylenimine), in the presence of
Optimem (Gibco), and the media replaced with 10 ml complete
DMEM after 6 h. Pseudoparticle-containing supernatants were recov-
ered after 72 h and passed through a 0.45 µM filter. From this, 100 µl
aliquots were used to infect 1.5103 HuH7 cells for 4 h in a 96-well
white plate (Corning). Following infection 200 µl DMEM was added to
the cells. Seventy-two hours following infection, media was discarded,
cells lysed with 50 µl Cell Lysis Buffer (Promega) and luminescence
assessed for each infection using a BMG Labtech FluoroStar Omega
luminometer. PMT gain was set to 3600 and 50 µl of Promega lucifer-
ase substrate was injected immediately before a 1 s luminescence read-
ing. Using this protocol, negative control readings following addition
of pseudotypes bearing no glycoproteins routinely resulted in a lumi-
nescence between 0 and 100 relative light units (RLUs), dependent on
the experiment. A total of 493 different E1/E2-encoding plasmids iso-
lated from 63 infected patients were screened for infectivity in HuH7
cells. Assigning a threshold of three times the background signal
achieved in the presence of pseudoparticles generated without glyco-
proteins, 118 were defined as infectious (Fig. 2). Subsequent analysis
was performed with clones representing viruses H77 (GenBank acces-
sion AF011751), UKN2A1.2 (AY734977), UKN1A14.40 (AY958061)
and UKN1A14.38 (AY958060). Particles were then produced using
varying amounts of both the E1/E2-encoding plasmid and the MLV
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packaging plasmid to optimize expression of each of the component
proteins, with a fixed amount (2 µg ml 1) of the reporter plasmid.
Plasmid quantities were between 8 and 0.0064 µg. In some experi-
ments, a pNL4.3 HIV-1 retrovirus backbone was used to manufacture
pseudoparticles as previously described (Hsu et al., 2003; McKeating
et al., 2004). Dose-dependent HCVpp neutralization experiments were
performed with the cross-neutralizing monoclonal antibody AP33 as
previously described (Owsianka et al., 2005). Infectivity plots were nor-
malized to the greatest luciferase signal achieved for each glycoprotein
construct (100%), and the luciferase signal achieved with a control
pseudoparticle preparation with glycoprotein plasmid omitted (0%)
using Graphpad Prism 6.0. These data were presented using Microsoft
Excel 2010 as three-dimensional plots with E1/E2-encoding plasmid
concentration on the x-axis, normalized luciferase signal on the y-axis
and packaging vector plasmid concentration on the z-axis.
Pseudoviruses, using similar experimental conditions to the HCVpp,
were also generated with glycoproteins corresponding to Zaire ebola-
virus H.sapiens-tc/COD/1976/Yambuku-Mayinga (Mayinga EBOV;
GenBank accession NC_002549) and Reston ebolavirus M.fascicularis-
tc/USA/1989/Philippines89-Pennsylvania (RESTV; GenBank accession
NC_004161), (Kobinger et al., 2001) both were kind gifts from Gary
Kobinger. A codon optimized construct for Zaire ebolavirus H.sapi-
ens-wt/GIN/2014/Makona-Gueckedou-C07 (Makona EBOV; GenBank
accession KJ660347.2) was also used, a kind gift from Etienne Simon-
Loriere. The ebolavirus glycoprotein-encoding genes were cloned into
the pcDNA3.1 plasmid and co-transfected with pTG126 and phCMV-
5349. Ebolavirus pseudoviruses (EBOVpv) were used to infect HuH7
cells similarly to HCVpp.
HCV pseudoparticles were pelleted by ultracentrifuging cell superna-
tants through a 20% sucrose cushion at 160 000 g (40 000 rpm in a
Beckman Type 70 Ti rotor) for 150min at 4

C. Pellets were resus-
pended in 50 µl PBS for analysis by Western blotting. Antibodies
AP33 and ALP98 (Owsianka et al., 2001) (kind gifts from Arvind
Patel) and a polyclonal rabbit anti-MLV capsid (a kind gift from Jean
Dubuission) were used to detect pseudoparticle-associated proteins
after separation on a 10% polyacrylamide gel.
HCVcc E1/E2 chimeras were generated as previously described
(McClure et al., 2016) in a genotype 1a Bi-gluc-H77c (1a)/JFH(T2700c
A4080T) chimeric virus (Reyes-del Valle et al., 2012) (a kind gift of
Charles Rice), encoding the Core/p7/NS2 of strain H77 and the E1/E2
glycoproteins of viruses screened by HCVpp assay. These constructs
possessed a Gaussia luciferase reporter. Infection assays with chimeric
viruses were performed essentially as previously described (Lindenbach
et al., 2005), determining infection by measuring luciferase expression
with a Biolux Gaussia Lucierase assay kit (NEB).
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